Article thumbnail

Peroxisome Proliferator-Activated Receptor-γ Ligands: Potential Pharmacological Agents for Targeting the Angiogenesis Signaling Cascade in Cancer

By Costas Giaginis, Anna Tsantili-Kakoulidou and Stamatios Theocharis

Abstract

Peroxisome proliferator-activated receptor-γ (PPAR-γ) has currently been considered as molecular target for the treatment of human metabolic disorders. Experimental data from in vitro cultures, animal models, and clinical trials have shown that PPAR-γ ligand activation regulates differentiation and induces cell growth arrest and apoptosis in a variety of cancer types. Tumor angiogenesis constitutes a multifaceted process implicated in complex downstream signaling pathways that triggers tumor growth, invasion, and metastasis. In this aspect, accumulating in vitro and in vivo studies have provided extensive evidence that PPAR-γ ligands can function as modulators of the angiogenic signaling cascade. In the current review, the crucial role of PPAR-γ ligands and the underlying mechanisms participating in tumor angiogenesis are summarized. Targeting PPAR-γ may prove to be a potential therapeutic strategy in combined treatments with conventional chemotherapy; however, special attention should be taken as there is also substantial evidence to support that PPAR-γ ligands can enhance angiogenic phenotype in tumoral cells

Topics: Review Article
Publisher: Hindawi Publishing Corporation
OAI identifier: oai:pubmedcentral.nih.gov:2366048
Provided by: PubMed Central

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.

Suggested articles

Citations

  1. (2006). 15-deoxy-Δ 12,14-prostaglandin J2 as a potential endogenous regulator of redox-sensitive transcription factors,”
  2. (2007). A considerationofPPAR-γ ligandswithrespecttolipophilicity: current trends and perspectives,”
  3. (2003). a n dB .M .E v e r s ,“ S e l e c t i v ea c t i v a t i o no fP P A R γ inhibits pancreatic cancer invasion and decreases expression of tissue plasminogen activator,”
  4. (1997). a n dS .A .K l i e w e r ,“ P e r o x i s o m ep r o l i f e r a t o r - a c t i v a t e dr e c e p -tors α and γ are activated by indomethacin and other non-steroidal anti-inflammatory drugs,”
  5. (2005). A SUMOylationdependent pathway mediates transrepression of inflammatory response genes by PPAR-γ,”
  6. (2002). A.BikfalviandR.Bicknell,“Recentadvancesinangiogenesis, anti-angiogenesis and vascular targeting,” Trends in Pharmacological Sciences,
  7. (2007). Activation of peroxisome proliferator-activated receptor-γ (PPARγ) by atorvastatin is mediated by 15-deoxy-Δ 12,14-PGJ2,” ProstaglandinsandOtherLipidMediators,v ol.84,no .1-2,pp .
  8. (1995). An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor γ (PPARγ),” J o u r n a lo fB i o l o g -ical Chemistry,
  9. (2006). and C.-H.Yang,“Rosiglitazoneinhibitsendothelialproliferationand angiogenesis,”
  10. (2007). Angiogenesis and antiangiogenic therapy in hematologic malignancies,”
  11. (2007). Angiogenesis in cancer: molecular mechanisms, clinical impact,”
  12. (2006). Angiogenesis—a new target for future therapy,”
  13. (2001). Angiogenesis: the role of the microenvironment in flipping the switch,”
  14. Anti-angiogenesis therapy can overcome endothelial cell anergy and promote leukocyte-endothelium interactions and infiltration in tumors,”
  15. (2004). Antiangiogenetic therapy with pioglitazone, rofecoxib, and metronomic trofosfamide in a patient with endemic Kaposi sarcoma,”
  16. (2003). Antiangiogenetic therapy with pioglitazone, rofecoxib, and metronomic trofosfamide in patients with advanced malignant vascular tumors,”
  17. (2006). Antiangiogenic effect of rosiglitazone is mediated via peroxisome proliferator-activated receptor γ-activated maxi-K channel opening in human umbilical vein endothelial cells,”
  18. (2004). Antitumor effects of peroxisome proliferator activate receptor gamma ligands on anaplastic thyroid carcinoma,”
  19. (2004). Bifunctional properties of peroxisome proliferator-activated receptor γ1 in KDR gene regulation mediated via interaction with both
  20. (1998). Biological action of leptin as an angiogenic factor,”
  21. (2004). Cancer without disease,”
  22. (2001). CD36: a class B scavenger receptor involved in angiogenesis, atherosclerosis, inflammation, and lipid metabolism,”
  23. (2007). Ciglitazone mediates COX2 dependent suppression of PGE2 in human non-small cell lung cancer cells,”
  24. (2006). Clinical implications of angiogenesis
  25. (2002). Defects of the heart, eye,andmegakaryocytesinperoxisomeproliferatoractivator receptor-binding protein (PBP) null embryos implicate GATA family of transcription factors,”
  26. (2002). Differential regulation of vascular endothelial growth factor expression by peroxisome proliferator-activated receptors in bladder cancer cells,”
  27. (2005). egur, “Transcriptional regulation of the vascular endothelial growth factor gene—a concert of activating factors,”Cardiovascular
  28. Endothelial cell apoptosis induced by the peroxisome proliferator- activated receptor (PPAR) ligand 15-deoxy-Δ 12,14-prostaglandin J2,”
  29. (2005). Endothelial extracellular matrix: biosynthesis, remodeling, and functions during vascularmorphogenesisandneovesselstabilization,”Circulation
  30. (1999). F r e e d ,A .A l l e n ,D .K .J o r k a s k y ,a n dR .A .D i c i c c o , “Systematic exposure to rosiglitazone is unaltered by food,”
  31. (2005). Fatty acid transduction of nitric oxide signaling: multiple nitrated unsaturated fatty acid derivatives exist in human blood and urine and serve as endogenous peroxisome proliferatoractivated receptor ligands,”
  32. (2006). From molecular action to physiological outputs: peroxisome proliferator-activated receptors are nuclear receptors at the crossroads of key cellular functions,”
  33. (2000). Gene expression profiling in an in vitro model of angiogenesis,”
  34. (2005). Growth stimulation of COX-2-negative pancreatic cancer by a selective COX-2 inhibitor,”
  35. (2007). Hypoxia reduces the expression and anti-inflammatory effects of peroxisome proliferator-activated receptor-γ in human proximal renal tubular cells,”
  36. (2007). Hypoxia: a ket regulator of angiogenesis in cancer,”
  37. (1998). i a n ,G .J .H a u s m a n ,M .M .C o m p t o n ,M .J .A z a i n ,D
  38. (2005). Inhibition of corneal neovascularization by a peroxisome proliferatoractivated receptor-γ ligand,”
  39. (2006). Inhibition of gastric cancer cells associated angiogenesis by 15d-prostaglandin J2 through the downregulation of angiopoietin-1,”
  40. (2006). Inhibition of hypoxia inducible factor-1α (HIF-1α) decreases vascular endothelial growth factor (VEGF) secretion and tumor growth in malignant gliomas,”
  41. (2007). Inhibitory effect of meloxicam, a selective cyclooxygenase-2 inhibitor, and ciglitazone, a peroxisome proliferator-activated receptor gamma ligand, on the growth of human ovarian cancers,”
  42. (1993). Interaction of the peroxisome proliferatoractivated receptor and retinoid X receptor,”
  43. (2007). Investigation of the lipophilic behaviour of some thiazolidinediones. Relationships with PPAR-γ activity,”
  44. (1994). K l i e w e r ,B .M .F o rm a n ,B .B l u m be r g,eta l . ,“ Di fferential expression and activation of a family of murine peroxisome proliferator-activated receptors,”
  45. (2002). Leptin induces endothelial cell migration through Akt, which is inhibited by PPARγ-ligands,”
  46. (2005). Ligands for peroxisome proliferator-activated receptor gamma have potent antitumor effect against human renal cell carcinoma,”
  47. (2000). Ligands of peroxisome proliferatoractivated receptor-γ increase the generation of vascular endothelial growth factor in vascular smooth muscle cells andinmacrophages,”ActaBiochimicaPolonica,v ol.47,no .4,
  48. (2001). Magnitude of peroxisome proliferator-activated receptor-γ activation is associated with important and seemingly opposite biological responses in breast cancer cells,”
  49. (2007). Mechanism of the anti-inflammatory effect of curcumin: PPAR-γ activation,”
  50. (2007). Modulation of the expression of peroxisome proliferators-activated receptors in human fibroblasts,”
  51. (2007). Molecular design and clinical development of VEGFR kinase inhibitors,”
  52. (2007). Molecular pathways of angiogenic inhibition,”
  53. (1998). N-(2-benzoylphenyl)-L-tyrosine PPARγ agonists. 1. Discovery of a novel series of potent antihyperglycemic and antihyperlipidemicagents,”JournalofMedicinalChemistry,vol.41,no.25,
  54. (2006). NF-κB regulation of endothelial cell function during LPS-induced toxemia and cancer,”
  55. Nitrolinoleic acid: an endogenous peroxisome proliferator-activated receptor γ ligand,”
  56. (2006). Novel high-affinity PPARγ agonist alone and in combination with paclitaxel inhibits human anaplastic thyroid carcinoma tumor growth via p21WAF1/CIP1,” Oncogene,
  57. (2007). PEDF induces p53-mediated apoptosis through PPAR gamma signaling in human umbilical vein endothelial cells,”
  58. (2003). Peroxisome proliferator activated receptor-γ (PPAR-γ) ligands and angiogenesis,”
  59. (2003). Peroxisome proliferator activated receptor-γ ligands as potent antineoplastic agents,”
  60. (2002). Peroxisome proliferator-activated receptor γ ligand inhibits cell growth and invasion of human pancreatic cancer cells,”
  61. (2007). Peroxisome proliferator-activated receptor γ: a novel target for cancer therapeutics?”
  62. (2000). Peroxisome proliferator-activated receptor-γ agonists increase vascular endothelial growth factor expression in human vascular smooth muscle cells,”
  63. (2007). Peroxisome proliferator-activated receptor-γ ligands as bone turnover modulators,”
  64. (2004). Peroxisome proliferator-activated receptor-γ ligands as cellcycle modulators,”
  65. (2007). Peroxisome proliferator-activated receptor-γ ligands as investigational modulators of angiogenesis,”
  66. (2004). Peroxisome proliferator-activated receptor-γ:therapeutictargetfordiseasesbeyonddiabetes:quo vadis?”ExpertOpiniononInvestigationalDrugs,vol.13,no .3,
  67. (1999). Peroxisome proliferator-activated receptors: nuclear control of metabolism,”
  68. (2005). Peroxisome proliferatoractivated receptor-γ (PPARγ) inhibits tumorigenesis by reversing the undifferentiated phenotype of metastatic nonsmall-cell lung cancer cells
  69. (2000). Peroxisome proliferatoractivated receptor-γ ligands inhibit choroidal neovascularization,”
  70. (2006). Peroxisome proliferatoractivated receptor-γ-agonist, rosiglitazone, promotes angiogenesis after focal cerebral ischemia,”
  71. (2005). Peroxisome proliterator-activated receptors in squamous cell carcinoma and its precursors,”
  72. (2006). Pioglitazone increases the numbers and improves the functional capacity of endothelial progenitor cells in patients with diabetes mellitus,”
  73. (2005). PPAR-γ activation inhibits angiogenesis by blocking ELR + CXC chemokine production in non-small cell lung cancer,”
  74. (2007). PPAR-γ agonists induce the expression of VEGF and its receptors in cultured cardiac myofibroblasts,”
  75. (2005). PPARγ as a therapeutic target for tumor angiogenesis and metastasis,” Cancer Biology and Therapy,v o l .4 ,n o .7 ,p p .
  76. (1999). PPARγ is required for placental, cardiac, and adipose tissue development,”
  77. (2003). PPARγ ligands and ATRA inhibit the invasion of human breast cancer cells in vitro,”
  78. (2002). PPARγ ligands inhibit primary tumor growth and metastasis by inhibiting angiogenesis,”JournalofClinicalInvestigation,vol.110,no.7,
  79. (2006). PPARγ represses VEGF expression in human endometrial cells: implications for uterine angiogenesis,”
  80. (2005). PPARγ-agonist rosiglitazone increases number and migratory activity of cultured endothelial progenitor cells,”
  81. (1990). Rapid increase in the use of oral antidiabetic drugs in the United States,
  82. (2005). Receptorindependent actions of PPAR thiazolidinedione agonists: is mitochondrial function the key?”
  83. (2006). Regulation of angiogenesis by hypoxia and hypoxia-inducible factors,”
  84. (1999). Regulation of gene expression by activation of the peroxisome proliferatoractivated receptor γ with rosiglitazone (BRL 49653) in human adipocytes,”
  85. (2001). Relation of vascular endothelial growth factor production to expression and regulation of hypoxia-inducible factor-1α and hypoxiainducible factor-2α in human bladder tumors and cell lines,”
  86. (2007). Rosiglitazone attenuates hypoxia-induced pulmonary arterial remodeling,”
  87. Statins upregulate CD36 expression in human monocytes, an effect strengthened when combined with PPAR-γ ligands
  88. (2007). Sutliff,a n dC .M .H a r t ,“ T h er o l eo f peroxisome proliferator-activated receptors
  89. (2002). The mechanisms of action of PPARs,”
  90. (2002). The peroxisome proliferator-activated receptor gamma ligand 15-deoxy-Δ 12,14-prostaglandin J2 induces vascular endothelial growth factor in the hormone-independent prostate cancer cell
  91. (1998). The peroxisome proliferator-activated receptorγ is a negative regulator of macrophage activation,”
  92. (2007). The PPAR-γ agonist pioglitazone increases neoangiogenesis and prevents apoptosis of endothelial progenitor cells,” Atherosclerosis,
  93. The PPARs: from orphan receptors to drug discovery,”
  94. (2000). The role of peroxisome proliferator-activated receptor γ in bladder cancer in relation to angiogenesis and progression,”
  95. (2007). Therapeutic approaches of angiogenesis inhibition: are we tackling the problem at the right level?”
  96. (2007). Thiazolidinediones in dermatology,”
  97. (2005). Thiazolidinediones inhibit proliferation of microvascular and macrovascular cells by a PPARγ-independent mechanism,”
  98. (1998). Tol´ o n ,A .I .C a s t i l l o ,a n dA .A r a n d a ,“ A c t i v a t i o n of the prolactin gene by peroxisome proliferator-activated receptor-αappearstobeDNAbinding-independent,”Journal of
  99. (2003). Tumorigenesis and the angiogenic switch,” Nature Reviews Cancer,v o l .3 ,n o .6 ,p p .
  100. (2004). u a n g ,S .C .C a m p b e l l ,D .F .B e d f o r d ,e ta l . ,“ P e r o x i s o m e proliferator-activated receptor γ ligands improve the antitumorefficacyofthrombospondinpeptideABT510,”Molecular Cancer Research,
  101. (2006). uhbeck, “Intracellular signalling pathways activated by leptin,”
  102. (2006). Upregulation of VEGF by 15-deoxy-Δ 12,14-prostaglandin J2 via heme oxygenase-1
  103. (2007). Vascular endothelial growth factors: biology and current status of clinical applications in cardiovascular medicine,”
  104. (2007). VEGF/ VEGFR signalling as a target for inhibiting angiogenesis,”
  105. (1999). X.Xin,S.Y ang,J .K owalski,andM.E.Gerritsen,“P ero xisome proliferator-activated receptor γ ligands are potent inhibitors of angiogenesis in vitro and in vivo,”